Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemedFRA:CXM 78 Return-on-Tangible-Asset is 34.30% as of Mar. 2026, which is 2% above its 10-year median of 33.67. GuruFocus rates FRA:CXM with a GF Score™ of 78/100 and a GF Value™ of €572.96 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 682 Healthcare Providers & Services companies, Chemed ranks better than 97.07% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Chemed's annualizedNet Income for the quarter that ended in Mar. 2026 was €229 Mil. Chemed's average total tangible assets for the quarter that ended in Mar. 2026 was €669 Mil. Therefore, Chemed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 34.30%.
The historical rank and industry rank for Chemed's Return-on-Tangible-Asset or its related term are showing as below:
FRA:CXM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 26.5 Med: 33.67 Max: 52.37
Current: 29.78
During the past 13 years, Chemed's highest Return-on-Tangible-Asset was 52.37%. The lowest was 26.50%. And the median was 33.67%.
FRA:CXM's Return-on-Tangible-Asset is ranked better than 97.07% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 2.465
vs FRA:CXM: 29.78
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Chemed Return-on-Tangible-Asset Related Terms
Chemed Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Chemed's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CXM vs PACS, LFST, CON: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Chemed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Chemed's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 34.30% mean?
Chemed (FRA:CXM) has a Return-on-Tangible-Asset of 34.30% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chemed and its competitors. This is near median its historical median of 33.67. Over the past decade, Chemed's Return-on-Tangible-Asset has ranged from 26.50 to 52.37. According to the industry distribution chart, Chemed ranks #20 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 2.9%.
Is Chemed's Return-on-Tangible-Asset too high?
Chemed's current Return-on-Tangible-Asset of 34.30% is near median its 10-year median of 33.67. Over the past 10 years, this metric has ranged from a low of 26.50 to a high of 52.37. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.47. Chemed's value of 34.30% is 1291.5% above this industry median. Based on the distribution chart, Chemed ranks #20 out of 682 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chemed has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Return-on-Tangible-Asset compare to PACS and LFST?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #20 out of 682 companies for Return-on-Tangible-Asset. This places Chemed in the top 3% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.47. Chemed's value of 34.30% is 1291.5% above this benchmark. Historically, Chemed's own Return-on-Tangible-Asset has ranged from 26.50 to 52.37 over the past decade. While the company's 10-year median is 33.67 vs. the industry median of 2.47, Chemed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.47, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current Return-on-Tangible-Asset of 34.30% is 1291.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current Return-on-Tangible-Asset is 34.30%, which is near median its own 10-year median of 33.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Modestly Undervalued. The stock's GF Value™ is €572.96, compared to a current price of €424.00 — trading 26% below its estimated fair value. The current Return-on-Tangible-Asset is 34.30%, which is near median its 10-year median of 33.67 and 1291.5% above the Healthcare Providers & Services industry median of 2.47. Chemed's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Return-on-Tangible-Asset is 34.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €424.00 is trading 26% below its estimated GF Value™ of €572.96.
GuruFocus considers Chemed to be Modestly Undervalued.
Key valuation signals for FRA:CXM:
Return-on-Tangible-Asset: 34.30% (near median its 10-year median of 33.67)
GF Value™: €572.96 vs. price of €424.00 (26% below fair value)
Industry Position: 1291.5% above the Healthcare Providers & Services median (#20 of 682)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
78GF Score
Get the complete analysis for FRA:CXM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
